Form 4: Director Richard Steinhart Receives Atossa Therapeutics RSU

Atossa Therapeutics director Richard I. Steinhart was granted 10,000 restricted stock units as part of his compensation.

Summary

• Director Richard I. Steinhart acquired 10,000 restricted stock units (RSUs) of Atossa Therapeutics, Inc. (ATOS).
• The transaction occurred on May 12, 2026.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs are scheduled to vest on the first anniversary of the grant date, May 12, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Future share price volatility may impact the ultimate value of the vested equity.

Future Outlook

The RSUs will vest on May 12, 2027, subject to the director's continued service.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice in the biotechnology sector to ensure long-term alignment between leadership and shareholder outcomes.

Comparison to Industry Standards

• The grant of RSUs to directors is a common practice among small-cap biotech firms to preserve cash while incentivizing board oversight.

Corporate Governance

Stakeholder Impact

• Minor dilution impact upon future vesting of shares.

Next Steps

• Vesting of 10,000 RSUs on May 12, 2027.

Key Dates

Keywords

Atossa Therapeutics, ATOS, Form 4, Insider Trading, Restricted Stock Units, Director Compensation